Core Viewpoint - Kenvue faces significant regulatory and reputational challenges due to unsubstantiated claims linking acetaminophen to autism during pregnancy, which threatens its Self-Care segment revenue [1][2] Company Overview - Kenvue, a consumer health company spun off from Johnson & Johnson in 2023, is defending the safety of acetaminophen, asserting that over a decade of research shows no credible evidence linking it to autism [2] - The company has experienced a market capitalization of $34 billion, but its stock has declined approximately 20% in 2025 due to concerns over market share erosion and litigation risks [4] Financial Performance - In Q2 of 2025, Kenvue reported a 4.2% decline in organic sales, with adjusted earnings narrowing from $0.32 per share to $0.29 per share over the last 12 months [5] Leadership Changes - Recent leadership changes, including the appointment of interim CEO Kirk Perry, who has over 30 years of experience in consumer packaged goods and technology, provide cautious optimism for the company's future [6] - The new leadership indicates a strategic pivot towards operational excellence and consumer-centric execution [6]

The gentleman from Wisconsin, Mr. . Style, who's also the chair of our subcommittee on digital assets, financial technology, and artificial intelligence. You're recognized for five minutes.Thank you, Chairman Hill. Thank you, Chairman Powell, for being with us today. I want to dive into two actions the Fed's recently taken uh to get a little additional color on.Yesterday, uh the Fed announced uh that reputational risk would no longer be a component in bank exams. Uh I viewed that positively. I viewed u the ...